Focused On-demand Library for Retinaldehyde-binding protein 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P12271

UPID:
RLBP1_HUMAN

ALTERNATIVE NAMES:
Cellular retinaldehyde-binding protein

ALTERNATIVE UPACC:
P12271; B2R667

BACKGROUND:
The function of Retinaldehyde-binding protein 1 centers on its role as a soluble retinoid carrier within the visual cycle, crucial for vision. It supports the regeneration of vital retinoids from their inactive forms, a process integral to maintaining the health of photoreceptor cells in the eye.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Retinaldehyde-binding protein 1 could open doors to potential therapeutic strategies. Its involvement in diseases like Bothnia retinal dystrophy and Retinitis punctata albescens highlights its potential as a target for developing treatments aimed at preserving or restoring vision.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7962 of 8789